Similasan, CVS, & Walgreens Eye Drops $3.58M Settlement

Similasan Corporation

If you purchased certain Similasan, CVS, or Walgreens homeopathic eye products in the United States between September 11, 2017, and February 20, 2025, you may be eligible to submit a claim for up to $10 or more from a class action settlement.

Similasan Corporation has agreed to pay $3,575,000 to settle a class action lawsuit for alleged deceptive labeling and advertising practices. The lawsuit, titled Plowden, et al. v. Similasan Corp., claims that the company marketed certain homeopathic eye products as "homeopathic" without obtaining proper approval from the U.S. Food and Drug Administration (FDA).

Additionally, the lawsuit alleges that these products were not manufactured according to Current Good Manufacturing Practices, were misleadingly advertised as sterile, and failed to disclose potential risks associated with the ingredient silver sulfate.

Who is eligible for an eye drop settlement payout?

You purchased at least one of the covered homeopathic eye products listed below in the United States and its territories.
The purchase occurred between September 11, 2017, and February 20, 2025.
The products purchased were for personal use only, not for resale.

The products included in this settlement are:

Similasan Dry Eye Relief
Similasan Complete Eye Relief
Similasan Allergy Eye Relief
Similasan Kids Allergy Eye Relief
Similasan Red Eye Relief
Similasan Pink Eye Relief
Similasan Kids Pink Eye Relief
Similasan Aging Eye Relief
Similasan Computer Eye Relief
Similasan Stye Eye Relief
Similasan Pink Eye Nighttime Gel
Similasan Dry Eye Nighttime Gel
CVS Pink Eye Drops
Walgreens Stye Eye Drops
Walgreens Pink Eye Drops
Walgreens Allergy Eye Drops

How much is the class action payment?

Without Proof of Purchase: Class members can claim up to a maximum of 4 products per household, at $2.50 per product, totaling $10 per household.
With Proof of Purchase: You can claim $2.50 per product with no limit on the number of products claimed, as long as proof of purchase for each claimed product is provided.

Final claim payout amounts will be adjusted on a pro rata basis, determined by the number of claims filed.

How to claim a Similasan, CVS, & Walgreens payout

To receive a class action rebate, you must submit a claim form. Class members can file a claim online or print the PDF claim form to complete and mail to the settlement administrator.

Settlement Administrator's mailing address: Homeopathic Eyedrop Settlement, Attn: Claim Form Submissions, 1650 Arch Street, Suite 2210, Philadelphia, PA 19103.

Claims must be submitted or postmarked by the October 15, 2025 deadline.

Required proof

With Proof of Purchase claims require supporting documentation such as store receipts, frequent shopper program records, or packaging that documents a Covered Product purchase on or before February 20, 2025.

Claim payment options

Class members can select from the following payment methods:

Prepaid Mastercard
Venmo
Zelle
Check

$3.58 Million eyedrop class action settlement fund

The settlement fund of $3,575,000 will include:

Attorneys' fees: Up to $1,191,666.67
Attorneys' litigation expenses: To be determined
Service awards to the three class representatives: $2,500 each, totaling $7,500
Settlement administration costs: At least $280,000
Payments to approved claimants: Remaining settlement balance

Important dates

Fairness Hearing: July 17, 2025
Deadline to File a Claim: October 15, 2025

When is the Homeopathic Eye Drop settlement payout date?

The final hearing is scheduled to take place on July 17, 2025. Payments to class members with valid claims will be issued after the court grants final approval, the claim deadline has passed, and processing is complete.

Why did CVS, Walgreens & Similasan agree to settle this class action?

The lawsuit alleged that Similasan deceptively marketed certain eye products as homeopathic without proper FDA approval, failed to comply with manufacturing standards, falsely advertised sterility, and did not disclose risks associated with silver sulfate. Similasan denies these allegations but agreed to a settlement in order to avoid the expense of continued litigation and the possibility of a trial.